Search Results - "Benkova, Katerina"

Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers by Benkova, Katerina, Mihalyova, Jana, Hajek, Roman, Jelinek, Tomas

“…Exportin 1 (XPO1), also known as chromosome maintenance 1 protein (CRM1), is the main transporter for hundreds of proteins like tumor suppressors, growth…”
Get full text

Single Cycle of Blinatumomab Followed By High-Dose Chemotherapy in the Induction Therapy for Ph-Negative Acute Lymphoblastic Leukemia in Adults. Primary Endpoint Analysis of the Blina-Cell Trial by Salek, Cyril, Folber, Frantisek, Hrabovsky, Stepan, Koristek, Zdenek, Horacek, Jan M, Fronkova, Eva, Soukup, Petr, Benkova, Katerina, Cetkovsky, Petr, Trka, Jan, Doubek, Michael

Get full text

Single‐agent venetoclax induces MRD‐negative response in relapsed primary plasma cell leukemia with t(11;14) by Jelinek, Tomas, Mihalyova, Jana, Kascak, Michal, Duras, Juraj, Popkova, Tereza, Benkova, Katerina, Richterova, Petra, Plonkova, Hana, Zuchnicka, Jana, Broskevicova, Lucie, Huvarova, Lucie, Cerna, Lucie, Growkova, Katerina, Simicek, Michal, Havel, Martin, Gumulec, Jaromir, Navratil, Milan, Koristek, Zdenek, Paiva, Bruno, Hajek, Roman

Get full text

Towards Higher Safety of Haemato-Oncological Patients Undergoing Treatment by Popkova, Tereza, Hradska, Katarina, Mihalyova, Jana, Skorupova, Michaela, Jelinek, Tomas, Duras, Juraj, Koristek, Zdenek, Navratil, Milan, Benkova, Katerina, Plonkova, Hana, Zuchnicka, Jana, Gumulec, Jaromir, Hajek, Roman

“…Introduction: Medical care has recently been moving from wards to outpatient clinics due to a growing number of patients, convenient therapeutic approaches and…”
Get full text

Venetoclax plus bortezomib and dexamethasone in heavily pretreated end‐stage myeloma patients without t(11;14): A real‐world cohort by Jelinek, Tomas, Popkova, Tereza, Duras, Juraj, Mihalyova, Jana, Kascak, Michal, Benkova, Katerina, Plonkova, Hana, Cerna, Lucie, Koristek, Zdenek, Simicek, Michal, Hajek, Roman

Get full text

Practical aspects of CAR-T cell therapy by Jana, Mihályová, Tomáš, Jelínek, Michal, Kaščák, Kateřina, Benková, Juraj, Uraš, Ivo, Demel, Zdeněk, Kořístek, Roman, Hájek

“…Chimeric antigen receptor (CAR) T cell therapy has been gradually building its position in the treatment of hematological malignancies. Currently, there are…”
Get more information